Format

Send to

Choose Destination
See comment in PubMed Commons below
J Cardiovasc Transl Res. 2013 Feb;6(1):46-53. doi: 10.1007/s12265-012-9413-4. Epub 2012 Oct 16.

iPS cell modeling of cardiometabolic diseases.

Author information

1
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. knakamura@partners.org

Abstract

Cardiometabolic diseases encompass simple monogenic enzyme deficiencies with well-established pathogenesis and clinical outcomes to complex polygenic diseases such as the cardiometabolic syndrome. The limited availability of relevant human cell types such as cardiomyocytes has hampered our ability to adequately model and study pathways or drugs relevant to these diseases in the heart. The recent discovery of induced pluripotent stem (iPS) cell technology now offers a powerful opportunity to establish translational platforms for cardiac disease modeling, drug discovery, and pre-clinical testing. In this article, we discuss the excitement and challenges of modeling cardiometabolic diseases using iPS cell and their potential to revolutionize translational research.

PMID:
23070616
PMCID:
PMC3547131
DOI:
10.1007/s12265-012-9413-4
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center